Andrea Slattery

Ms. Slattery is a senior investment professional with over 20 years of experience investing in public and private technology companies. Ms. Slattery is currently a Partner and Director of Research at Symmetry Peak Management, an investment firm focused on technology and emerging growth companies. Symmetry Peak has returned over 8x net to investors since inception in 2003. She led the firms’ outsized and early positions in Amazon, Apple, Aruba Networks, Baidu, Google, Mellanox, Netease, and Salesforce, and also created and implemented the firm’s macro risk management practice which has been instrumental in managing gross and net exposures since 2009.

From 2004 to 2008, Ms. Slattery was one of four Senior Partners at Ardsley Partners, where she co-managed the technology portion of the approximately $1 billion long/short equity fund, and was a top performing Partner during her time with the firm.

Prior to her tenure at Ardsley, Ms. Slattery was the second in command at Alkeon Capital Management LLC, a technology-focused long/short equity fund. At Alkeon, Ms. Slattery helped to design and build the research process and team, and was directly responsible for a significant portion of both the long and short books, as the firm grew from $40 million to approximately $1.2 billion.

Ms. Slattery began her career in 1998 as a buy-side technology generalist at CIBC Oppenheimer, working with the fund and team that was later spun out to form Alkeon in 2002.

Ms. Slattery is a CFA® charterholder, and graduated summa cum laude with a BSBA degree from Washington University in St. Louis, Missouri.

Philanthropically, Ms. Slattery serves on the board of The LAM Foundation, a non-profit organization dedicated to finding better treatments and ultimately a cure for lymphangioleiomyomatosis (LAM), a rare lung disease that affects women. Her service to The LAM Foundation included 2 full terms as Board Chair, as well as serving on both the Executive and Development Committees. She was instrumental in upgrading the Foundation’s technology infrastructure, and substantially raising the awareness and profile of The LAM Foundation within the rare disease community. During her tenure as Board Chair, and due to the incredible scientific leadership, The LAM Foundation received FDA approval for a safe and effective treatment for the disease, a distinction less than 7% of rare diseases can claim. Ms. Slattery’s passion is to continue to apply her experience in the technology industry towards enhancing patient knowledge and accelerating advances in rare disease research.